Second pivotal Phase III study of Piclidenoson
Latest Information Update: 27 Mar 2025
At a glance
- Drugs Piclidenoson (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
Most Recent Events
- 24 Mar 2025 According to a Can-Fite BioPharma media release, the Company plans to submit a New Drug Application (NDA) to the U.S. FDA and Marketing Authorization Plan (MAA) to the EMA, after positive conclusion of the Phase 3 program.
- 18 Dec 2023 According to a Can-Fite BioPharma media release, the company received a positive response from the U.S. Food and Drug Administration (FDA) on the Pediatric Study Plan for the treatment of children suffering from psoriasis with Piclidenoson. The plan has been submitted to allow enrollment of children with psoriasis to one or both of the Phase 3 studies.
- 05 Jul 2023 New trial record